Cross-linked collagen C- and N-telopeptides for an early diagnosis of bone metastasis from breast cancer

2002 ◽  
Author(s):  
Konosuke Kiuchi ◽  
Takashi Ishikawa ◽  
Yohei Hamaguchi ◽  
Nobuyoshi Momiyama ◽  
Satoshi Hasegawa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Early Diagnosis ◽  
C And N ◽  
Diagnosis Of Bone Metastasis

Periodic measurement of N-telopeptides of type I collogen in serum (sNTx) for early diagnosis of bone metastasis in patients with lung cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e18042-e18042
Author(s):  
Koji Takeda ◽  
Shinya Tokunaga ◽  
Haruko Daga ◽  
Hideaki Okada ◽  
Koichi Taira ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Bone Metastasis ◽  
Early Diagnosis ◽  
Bone Scintigraphy ◽  
Type I ◽  
Clinical Implementation ◽  
Significant Difference ◽  
The Mean ◽  
Diagnosis Of Bone Metastasis

e18042 Background: The bone resorption biomarker sNTx has been previously shown to add value as an aid in the diagnosis of bone metastasis in patients with lung cancer. The objective of this prospective study was to determine if periodic sNTx measurements could lead to early diagnosis of bone metastasis in patients with lung cancer. Methods: Patients with newly diagnosed organ-confined lung cancer were enrolled. sNTx values were determined once each month using the OSTEOMARKTM serum NTx assay (Alere Medical). The presence or absence of bone metastasis was determined by monthly physical examination and by bone scintigraphy every 3 months for 12 months. All patients were required to provide written informed consent. Results: Forty patients were enrolled between June and December 2010. One patient withdrew early and was excluded from analysis. The mean +/- 1 SD baseline level of sNTx was 17.5 +/- 4.4 nM BCE/L. Five patients developed bone metastasis (as characterized by bone scintigraphy) during the study period. The level of sNTx in subjects with bone metastasis was slightly increased (21.6 +/- 3.2 nM BCE/L), however, in these patients, there was no statistically significant difference between sNTx values at baseline (18.2 +/- 4.2 nM BCE/L) and when metastasis was diagnosed. (p=0.176). When a cut-off value of sNTx was set to 22.0 nM BCE/L, the sensitivity and the specificity of detection of bone metastasis were 80.0% and 41.2%, respectively. Using this cut-off, the elevation of sNTx could predict bone metastasis at least one month before diagnosis by bone scintigraphy in all 5 patients, however, the specificity was relatively low for clinical implementation. Additionally, the sensitivity and the specificity of early detection of systematic spread of disease (including bone metastasis) were 70.6% and 45.5%, respectively. Conclusions: Periodic determination of sNTx in patients with organ confined lung cancer did not provide sufficient specificity for it to be used for the early diagnosis of bone metastasis or disease progression.

Multiparametric Biochemical Study in the Diagnosis of Bone Metastasis of Breast Cancer

Metastasis ◽  
1980 ◽  
pp. 341-345
Author(s):  
J. L. Boublil ◽  
G. Milano ◽  
M. Namer ◽  
M. Viot ◽  
A. Ramaioli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Biochemical Study ◽  
Diagnosis Of Bone Metastasis

The Advantage of a Combined SPECT/CT in the Diagnosis of Bone Metastases

2017 ◽  
Vol 62 (5) ◽  
pp. 33-39 ◽  
Author(s):  
А. РЫжков ◽  
A. RYzhkov ◽  
А. Крылов ◽  
A. Krylov ◽  
С. Ширяев ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Bone Metastasis ◽  
Bone Metastases ◽  
Multiple Metastases ◽  
Cancer Prostate ◽  
Diagnostic Capabilities ◽  
Diagnosis Of Bone Metastasis

Purpose: To define the diagnostic capabilities of SPECT/CT in comparison with WBS in patients with bone metastases. Material and methods: It was included 67 patients with bone metastases of breast cancer, prostate cancer and other tumors. The evaluation was included WBS and SPECT/CT. Results: All patients were divided into 2 groups: with single and multiple metastases. SPECT/CT showed higher efficiency in detecting bone metastases than WBS. The full detection of bone metastases with WBS ranged from 31 to 56 % compared to SPECT/CT for groups respectively. In some cases (for groups respectively 4 % to 9.5 % depending on the number of metastases and their localization) of WBS was not informative, recorded the absence of lesions. Conclusion: SPECT/CT can improve the diagnosis of bone metastasis.

Increased COX2 expression enhances tumor-induced osteoclastic lesions in breast cancer bone metastasis

2008 ◽  
Vol 68 (S 01) ◽  
Author(s):  
C Schem ◽  
DO Bauerschlag ◽  
J Weimer ◽  
M Zhang ◽  
W Jonat ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Breast Cancer Bone Metastasis ◽  
Cox2 Expression
Sign in / Sign up

Export Citation Format

Share Document